Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Assets (2016 - 2025)

RedHill Biopharma has reported Other Non-Current Assets over the past 15 years, most recently at $169000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets rose 14.19% to $169000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $169000.0 through Dec 2025, up 14.19% year-over-year, with the annual reading at $169000.0 for FY2025, 14.19% up from the prior year.
  • Other Non-Current Assets was $169000.0 for Q4 2025 at RedHill Biopharma, up from $160000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $16.2 million in Q4 2021 and troughed at $148000.0 in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $16.0 million (2022), against an average of $10.1 million.
  • Year-over-year, Other Non-Current Assets tumbled 95.06% in 2023 and then grew 14.19% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $16.2 million in 2021, then decreased by 1.05% to $16.0 million in 2022, then tumbled by 95.06% to $790000.0 in 2023, then crashed by 81.27% to $148000.0 in 2024, then grew by 14.19% to $169000.0 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Other Non-Current Assets are $169000.0 (Q4 2025), $160000.0 (Q2 2025), and $148000.0 (Q4 2024).